M. Ducreux, A. S. Cuhna, C. Caramella, A. Hollebecque, P. Burtin et al., ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.56-68, 2015.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, pp.2913-2934, 2014.

P. Seshacharyulu, M. J. Baine, J. J. Souchek, M. Menning, S. Kaur et al., Biological determinants of radioresistance and their remediation in pancreatic cancer, Biochim Biophys Acta, vol.1868, pp.69-92, 2017.

L. Buckel, E. N. Savariar, J. L. Crisp, K. A. Jones, A. M. Hicks et al., Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery, Cancer Res, vol.75, pp.1376-87, 2015.

S. R. Adams, H. C. Yang, E. N. Savariar, J. Aguilera, J. L. Crisp et al., Anti-tubulin drugs conjugated to antiErbB antibodies selectively radiosensitize, Nat Commun, vol.7, p.13019, 2016.

H. Safran, D. Iannitti, R. Ramanathan, J. D. Schwartz, M. Steinhoff et al., Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu, Cancer Invest, vol.22, pp.706-718, 2004.

P. A. Philip, J. Benedetti, C. L. Corless, R. Wong, E. M. O'reilly et al., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205, J Clin Oncol, vol.28, pp.3605-3615, 2010.

H. Friess, Y. Yamanaka, M. S. Kobrin, D. A. Do, M. W. Büchler et al., Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res, vol.1, pp.1413-1433, 1995.

J. P. Arnoletti, D. J. Buchsbaum, Z. Huang, A. E. Hawkins, M. B. Khazaeli et al., Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells, J Gastrointest Surg, vol.8, pp.969-970, 2004.

J. S. Liles, J. P. Arnoletti, C. Tzeng, J. H. Howard, A. V. Kossenkov et al., ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma, Cancer Biol Ther, vol.10, pp.555-63, 2010.

J. B. Fitzgerald, B. W. Johnson, J. Baum, S. Adams, S. Iadevaia et al., MM-141, an IGF-IR-and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors, Mol Cancer Ther, vol.13, pp.410-435, 2014.

A. J. Camblin, E. A. Pace, S. Adams, M. D. Curley, V. Rimkunas et al., Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer, Clin Cancer Res, 2018.

J. S. Liles, J. P. Arnoletti, A. V. Kossenkov, A. Mikhaylina, A. R. Frost et al., Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma, Br J Cancer, vol.105, pp.523-556, 2011.

J. N. Contessa, A. Abell, R. B. Mikkelsen, K. Valerie, and R. K. Schmidt-ullrich, Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation, Breast Cancer Res Treat, vol.95, pp.17-27, 2006.

C. Li, T. M. Brand, M. Iida, S. Huang, E. A. Armstrong et al., Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma, Discov Med, vol.16, pp.79-92, 2013.

C. Li, S. Huang, E. A. Armstrong, D. M. Francis, L. R. Werner et al., Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers, Mol Cancer Ther, vol.14, pp.2049-59, 2015.

H. Dote, D. Cerna, W. E. Burgan, K. Camphausen, and P. J. Tofilon, ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition, Cancer Res, vol.65, pp.6967-75, 2005.

L. Clorennec, C. Bazin, H. Dubreuil, O. Larbouret, C. Ogier et al., Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3, vol.16, pp.1312-1335, 2017.

Y. Lazrek, O. Dubreuil, V. Garambois, N. Gaborit, C. Larbouret et al., Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKTinduced MDM2, XIAP, and FoxO1 phosphorylation, Neoplasia, vol.15, pp.335-382, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00815985

G. Thomas, T. Chardès, N. Gaborit, C. Mollevi, W. Leconet et al., HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models, Oncotarget, vol.5, pp.7138-7186, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01075330

L. Clorennec, C. Lazrek, Y. Dubreuil, O. Larbouret, C. Poul et al., The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2-dependent ITCH/AIP4 activation, Oncotarget, 2016.

T. Terasima and L. J. Tolmach, Variations in several responses of HeLa cells to x-irradiation during the division cycle, Biophys J, vol.3, pp.11-33, 1963.

S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny et al., Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat Biotechnol, vol.21, pp.778-84, 2003.

W. Leconet, C. Larbouret, T. Chardès, G. Thomas, M. Neiveyans et al.,

, Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy, Oncogene, vol.33, pp.5405-5419, 2014.

M. C. Ryan, H. Kostner, K. A. Gordon, S. Duniho, M. K. Sutherland et al., Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75, Br J Cancer, vol.103, pp.676-84, 2010.

S. J. Scales, N. Gupta, G. Pacheco, R. Firestein, D. M. French et al., An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models, Mol Cancer Ther, vol.13, pp.2630-2670, 2014.

Y. Koga, S. Manabe, Y. Aihara, R. Sato, R. Tsumura et al., Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts, Int J Cancer, vol.137, pp.1457-66, 2015.

P. M. Challita-eid, D. Satpayev, P. Yang, Z. An, K. Morrison et al., Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models, Cancer Res, vol.76, pp.3003-3016, 2016.

M. Mattie, A. Raitano, K. Morrison, K. Morrison, Z. An et al., The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer, Mol Cancer Ther, vol.15, pp.2679-87, 2016.

H. Yao, L. Feng, J. Zhou, R. Zhang, and M. Wang, Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment, Am J Cancer Res, vol.6, pp.937-56, 2016.

P. Strop, T. Tran, M. Dorywalska, K. Delaria, R. Dushin et al., Site-Specific Trop-2 AntibodyDrug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models, Mol Cancer Ther, vol.15, pp.2698-708, 2016.

A. Kumari, S. S. Simon, T. D. Moody, and C. Garnett-benson, Immunomodulatory effects of radiation: what is next for cancer therapy?, Future Oncol, vol.12, pp.239-56, 2016.

M. M. Wattenberg, A. R. Kwilas, S. R. Gameiro, A. P. Dicker, and J. W. Hodge, Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets, Br J Cancer, vol.110, pp.1472-80, 2014.

P. P. Adiseshaiah, R. M. Crist, S. S. Hook, and S. E. Mcneil, Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer, Nat Rev Clin Oncol, vol.13, pp.750-65, 2016.

C. A. Znati, M. Rosenstein, Y. Boucher, M. W. Epperly, W. D. Bloomer et al., Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft, Cancer Res, vol.56, pp.964-972, 1996.

S. Huang, C. Li, E. A. Armstrong, C. R. Peet, J. Saker et al., Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation, Cancer Res, vol.73, pp.824-857, 2013.

D. M. Francis, S. Huang, E. A. Armstrong, L. R. Werner, C. Hullett et al., Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models, Clin Cancer Res, vol.22, pp.633-676, 2016.

Y. Yan, A. L. Hein, P. M. Greer, Z. Wang, R. H. Kolb et al., A novel function of HER2/Neu in the activation of G2/M checkpoint in response to ?-irradiation, Oncogene, vol.34, pp.2215-2241, 2015.

C. M. Silva, Role of STATs as downstream signal transducers in Src family kinasemediated tumorigenesis, Oncogene, vol.23, pp.8017-8040, 2004.

M. Spitzner, R. Ebner, H. A. Wolff, B. M. Ghadimi, J. Wienands et al., STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy, Cancers (Basel), vol.6, pp.1986-2011, 2014.

J. A. Francisco, C. G. Cerveny, D. L. Meyer, B. J. Mixan, K. Klussman et al., cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity, Blood, vol.102, pp.1458-65, 2003.
DOI : 10.1182/blood-2003-01-0039

URL : http://www.bloodjournal.org/content/102/4/1458.full.pdf

E. Capone, F. Giansanti, S. Ponziani, A. Lamolinara, M. Iezzi et al., EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma, Oncotarget, vol.8, pp.95412-95436, 2017.

E. Capone, A. Lamolinara, D. 'agostino, D. Rossi, C. et al., EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma, J Control Release, vol.277, pp.48-56, 2018.

T. Kogawa, K. Yonemori, Y. Naito, E. Noguchi, C. Shimizu et al., Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-class study of U3-1402 (anti-HER3 antibody-drug conjugate) in subjects with HER3-positive metastatic breast cancer, J Clin Oncol, vol.35, p.60, 2017.

K. Yonesaka, N. Takegawa, S. Watanabe, K. Haratani, H. Kawakami et al., An HER3-targeting antibodydrug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC, Oncogene [Internet], 2018.
DOI : 10.1038/s41388-018-0517-4

A. Drilon, R. Somwar, B. P. Mangatt, H. Edgren, P. Desmeules et al., Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers, Cancer Discov, vol.8, pp.686-95, 2018.
DOI : 10.1158/2159-8290.cd-17-1004

URL : http://cancerdiscovery.aacrjournals.org/content/candisc/8/6/686.full.pdf

K. Yonesaka, K. Hirotani, J. Von-pawel, M. Dediu, S. Chen et al., Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer, Lung Cancer, vol.105, pp.1-6, 2017.

A. Beck, L. Goetsch, C. Dumontet, and N. Corvaïa, Strategies and challenges for the next generation of antibody-drug conjugates, Nat Rev Drug Discov, vol.16, pp.315-352, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01567797

, Down-(blue) or up-regulation (red) was calculated relative to the 100% normal expression in control cells (medium alone; white). (B) Western blot analysis of proteins involved in the DNA damage repair, survival and apoptosis pathways. BxPC3 cells were incubated with 1?g/ml HER3-ADC 24h before irradiation (2Gy) (IR). Cells were harvested and lysed 1h and 24h post-irradiation